TG Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• TG Therapeutics Inc TGTX.OQ reported quarterly adjusted earnings of 3 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -7 cents. The mean expectation of seven analysts for the quarter was for earnings of 18 cents per share. Wall Street expected results to range from 12 cents to 28 cents per share.

• Revenue rose 90.4% to $120.86 million from a year ago; analysts expected $118.43 million.

• TG Therapeutics Inc's reported EPS for the quarter was 3 cents​.

• The company reported quarterly net income of $5.06 million.

• TG Therapeutics Inc shares had risen by 10.2% this quarter and gained 44.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 22.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for TG Therapeutics Inc is $46.00

This summary was machine generated from LSEG data May 5 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)